Biogenix Molecular, LLC | Miami, FL

Research site

(Unclaimed)

Location

2720 SW 97th Avenue, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

Gadoquatrane

Debio 4228

FPI-2265

RYZ101

BAY3547922

177Lu-PSMA-617

BAY3630942

[Lu-177]-PNT2002

64Cu-SAR-BBN

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 10 total trials

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-express...

Enrolling

Castration-Resistant

Prostatic Neoplasms

Drug: 64Cu-SAR-BBN

Drug: 67Cu-SAR-BBN

A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer

The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.

Enrolling

Prostate Cancer

Drug: Debio 4228

A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer

Researchers are studying a new potential treatment for liver cancer.To do this, researchers have developed a protein, called a monoclonal antibody, w...

Begins enrollment this month

Hepatocellular Carcinoma (HCC)

Drug: BAY3547922

Drug: BAY3630942

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak)

This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). The dose optimization Phase 2 part will be investigating the safe...

Enrolling

Metastatic Castration-resistant Prostate Cancer

Drug: FPI-2265

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and...

Active, not recruiting

Gastroenteropancreatic Neuroendocrine Tumor

Pancreatic NET

Drug: Octreotide LAR 60 MG Injection

Drug: Lanreotide 120Mg Sa Susp Inj Syringe

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms